Showing results (161-170 of 253) with videos related to
Sort By:
Pageof 26
Nature Immunology|September 6, 2011
Human cytomegalovirus microRNA miR-US4-1 inhibits CD8(+) T cell responses by targeting the aminopeptidase ERAP1Sungchul Kim, Sanghyun Lee, Jinwook Shin, et al.Plos One|May 6, 2014
Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatmentKendall C Shibuya, Vikas K Goel, Wei Xiong, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2016
Analysis of ROR1 Protein Expression in Human Cancer and Normal TissuesAshwini Balakrishnan, Tracy Goodpaster, Julie Randolph-Habecker, et al.Journal for Immunotherapy of Cancer|April 10, 2020
Histiocyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapyBrett A Schroeder, Ralph Graeme Black, Sydney Spadinger, et al.Plos One|December 21, 2013
Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphomaLihua E Budde, Carolina Berger, Yukang Lin, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 13, 2019
Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell TherapyJulia Ruark, Erin Mullane, Nancy Cleary, et al.Science (New York, N.Y.)|September 9, 2006
An antigen produced by splicing of noncontiguous peptides in the reverse orderEdus H Warren, Nathalie J Vigneron, Marc A Gavin, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 28, 2017
Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture ConditionsSang Yun Lee, Philip Olsen, Dong Hoon Lee, et al.Future Oncology (London, England)|June 22, 2021
Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignanciesNina Shah, Miguel-Angel Perales, Cameron J Turtle, et al.Blood Advances|December 5, 2022
Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor functionIsabel Leung, Megan L Templeton, Yun Lo, et al.Pageof 26